Key facts
- This page summarizes Mark J. Vignola's Form 4 filing for Terns Pharmaceuticals, Inc. (TERN).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 06 Jan 2025, 19:30.
Mark J. Vignola - 02 Jan 2025 Form 4 Insider Report for Terns Pharmaceuticals, Inc. (TERN)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- TERN
- Reported as of
- 02 Jan 2025
- Net transaction value
- -$99,024
- SEC form
- 4
- Accepted by SEC
- 06 Jan 2025, 19:30:43 UTC
- Prior SEC filing
- 12 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Strauss, as Attorney-in-Fact for Mark J. Vignola
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Mark J. Vignola filed Form 4 for Terns Pharmaceuticals, Inc. (TERN) on 06 Jan 2025.
Change
- Previous filing in this sequence was filed on 12 Sep 2024.
- Current net transaction value: -$99,024.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TERN
transaction
Common Stock
Sale
- Transaction value
- $46,524
- Shares
- -8,129
- Change %
- -8.8%
- Price
- $5.72
- Shares after
- 83,811
- Date
- 02 Jan 2025
- Ownership
- Direct
- Footnotes
- F1, F2
TERN
transaction
Common Stock
Sale
- Transaction value
- $52,500
- Shares
- -9,059
- Change %
- -11%
- Price
- $5.80
- Shares after
- 74,752
- Date
- 06 Jan 2025
- Ownership
- Direct
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
Represents shares of common stock sold to satisfy taxes associated with the vesting of a restricted stock unit award previously granted to the Reporting Person. Such sales do not represent a discretionary trade by the Reporting Person.
Footnote F2
This sale price represents the weighted average sale price of the shares sold ranging from $5.64 to $5.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Footnote F3
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2024.
Footnote F4
This sale price represents the weighted average sale price of the shares sold ranging from $5.66 to $5.95 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.